Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.
Andrea K ViecelliKevan R PolkinghorneElaine M PascoePeta-Anne Paul-BrentCarmel M HawleySunil V BadveAlan CassLai-Seong HooiPeter G KerrTrevor A MoriLoke-Meng OngDavid VossDavid Wayne JohnsonAshley B Irishnull nullPublished in: PloS one (2019)
Although fish oil and low-dose aspirin given for 3 months reduced intervention rates in newly created AVF, they had no significant effects on CVC exposure, AVF usability and time to primary patency loss or access abandonment. Reduction in access interventions benefits patients, reduces costs and warrants further study.
Keyphrases
- low dose
- fatty acid
- end stage renal disease
- clinical trial
- high dose
- study protocol
- cardiovascular events
- randomized controlled trial
- antiplatelet therapy
- chronic kidney disease
- ejection fraction
- open label
- physical activity
- peritoneal dialysis
- metabolic syndrome
- health information
- phase ii
- cardiovascular disease
- double blind
- electronic health record
- percutaneous coronary intervention
- adipose tissue
- social media
- patient reported
- weight loss